$8.62
2.32%
Downside
Day's Volatility :3.77%
Upside
1.49%
35.61%
Downside
52 Weeks Volatility :68.91%
Upside
51.71%
Period | Paragon 28, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.7% | 6.5% | 0.0% |
6 Months | -29.56% | 7.1% | 0.0% |
1 Year | -49.27% | 9.8% | 0.0% |
3 Years | -53.77% | 14.2% | -20.2% |
Market Capitalization | 688.5M |
Book Value | $1.98 |
Earnings Per Share (EPS) | -0.65 |
Wall Street Target Price | 16.0 |
Profit Margin | -23.96% |
Operating Margin TTM | -21.12% |
Return On Assets TTM | -8.19% |
Return On Equity TTM | -29.23% |
Revenue TTM | 225.4M |
Revenue Per Share TTM | 2.73 |
Quarterly Revenue Growth YOY | 17.4% |
Gross Profit TTM | 148.9M |
EBITDA | -25.8M |
Diluted Eps TTM | -0.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.58 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 85.61%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 106.3M | - |
Net Income | 3.1M | - |
Net Profit Margin | 2.93% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 111.0M | ↑ 4.42% |
Net Income | 2.7M | ↓ 13.83% |
Net Profit Margin | 2.42% | ↓ 0.51% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 147.5M | ↑ 32.87% |
Net Income | -13.7M | ↓ 609.79% |
Net Profit Margin | -9.29% | ↓ 11.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 181.4M | ↑ 23.0% |
Net Income | -67.3M | ↑ 391.68% |
Net Profit Margin | -37.12% | ↓ 27.83% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 216.4M | ↑ 19.3% |
Net Income | -47.8M | ↓ 28.94% |
Net Profit Margin | -22.11% | ↑ 15.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 51.5M | ↑ 11.96% |
Net Income | -38.8M | ↑ 298.63% |
Net Profit Margin | -75.26% | ↓ 54.12% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 52.0M | ↑ 1.03% |
Net Income | -9.1M | ↓ 76.65% |
Net Profit Margin | -17.4% | ↑ 57.86% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 51.0M | ↓ 1.97% |
Net Income | -10.9M | ↑ 20.39% |
Net Profit Margin | -21.36% | ↓ 3.96% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 52.8M | ↑ 3.48% |
Net Income | -8.3M | ↓ 23.55% |
Net Profit Margin | -15.79% | ↑ 5.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 60.6M | ↑ 14.74% |
Net Income | -19.6M | ↑ 134.75% |
Net Profit Margin | -32.3% | ↓ 16.51% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 61.1M | ↑ 0.86% |
Net Income | -15.2M | ↓ 22.11% |
Net Profit Margin | -24.94% | ↑ 7.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 74.6M | - |
Total Liabilities | 47.3M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 97.6M | ↑ 30.89% |
Total Liabilities | 26.1M | ↓ 44.83% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 234.5M | ↑ 140.35% |
Total Liabilities | 42.4M | ↑ 62.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 254.1M | ↑ 8.34% |
Total Liabilities | 113.2M | ↑ 167.25% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 340.7M | ↑ 34.08% |
Total Liabilities | 163.0M | ↑ 43.98% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 254.1M | ↓ 1.11% |
Total Liabilities | 113.2M | ↑ 32.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 313.5M | ↑ 23.39% |
Total Liabilities | 108.4M | ↓ 4.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 300.8M | ↓ 4.05% |
Total Liabilities | 101.8M | ↓ 6.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 293.4M | ↓ 2.49% |
Total Liabilities | 99.6M | ↓ 2.15% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 340.7M | ↑ 16.14% |
Total Liabilities | 163.0M | ↑ 63.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 334.6M | ↓ 1.79% |
Total Liabilities | 170.1M | ↑ 4.39% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 12.3M | - |
Investing Cash Flow | -17.5M | - |
Financing Cash Flow | 6.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1M | ↓ 90.97% |
Investing Cash Flow | -10.3M | ↓ 40.88% |
Financing Cash Flow | 24.0M | ↑ 266.88% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.3M | ↓ 398.56% |
Investing Cash Flow | -35.5M | ↑ 243.96% |
Financing Cash Flow | 131.1M | ↑ 445.96% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -49.2M | ↑ 1382.7% |
Investing Cash Flow | -60.7M | ↑ 71.01% |
Financing Cash Flow | 39.5M | ↓ 69.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.2M | ↑ 9.25% |
Investing Cash Flow | -7.2M | ↑ 29.33% |
Financing Cash Flow | 2.6M | ↑ 109.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↑ 6.27% |
Investing Cash Flow | -7.6M | ↑ 5.27% |
Financing Cash Flow | 69.4M | ↑ 2620.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↑ 37.57% |
Investing Cash Flow | -15.3M | ↑ 102.11% |
Financing Cash Flow | -2.5M | ↓ 103.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↓ 27.03% |
Investing Cash Flow | -22.0M | ↑ 44.34% |
Financing Cash Flow | -1.4M | ↓ 46.73% |
Sell
Neutral
Buy
Paragon 28, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Paragon 28, Inc. | 37.74% | -29.56% | -49.27% | -53.77% | -53.77% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Paragon 28, Inc. | NA | NA | NA | -0.58 | -0.29 | -0.08 | NA | 1.98 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Paragon 28, Inc. | Buy | $688.5M | -53.77% | NA | -23.96% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Paragon 28, Inc.
Revenue is up for the last 4 quarters, 51.00M → 61.08M (in $), with an average increase of 5.7% per quarter
Netprofit is up for the last 2 quarters, -19.55M → -15.23M (in $), with an average increase of 28.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 91.0%
MVM Partners LLC
First Light Asset Management, LLC
BlackRock Inc
BRAIDWELL LP
Vanguard Group Inc
Bleichroeder LP
paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen
Organization | Paragon 28, Inc. |
Employees | 574 |
CEO | Mr. Albert DaCosta |
Industry | Healthcare |